B., Del Prato, S., Kahn, S
In many clinical circles, experts prefer the term "skin lightening" or "brightening" because the goal is often to reduce hyperpigmentation, dark spots, and dullness rather than changing one's natural ethnic skin tone entirely
With compounded semaglutide, despite being produced by legitimate pharmacies, the absence of FDA approval means less scrutiny regarding purity, potency, and sterile compounding practices
It is important to note that while hemorrhoids can often be managed with over-the-counter treatments and lifestyle changes, symptoms that persist or worsen may indicate complications such as thrombosed hemorrhoids, which can lead to increased pain and swelling
Ozempic may also change the gut microbiome itself in some people, which can cause a diarrheal effect
p 9.5% Baseline characteristics Average age 54 years Average BMI - 36 Average weight - 220 lbs (100 kg) Type 2 diabetes - 58% Average NAFLD activity score - 5.3 Liver fibrosis stage: F2 - 43% | F3 - 57% Randomized treatment groups Group 1 (47 patients): Tirzepatide 5 mg once weekly Group 2 (47patients): Tirzepatide 10 mg once weekly Group 3 (48 patients): Tirzepatide 15 mg once weekly Group 4 (48 patients): Placebo Therapy was initiated at 2.5 mg, and patients were titrated to their assigned dose in 2.5 mg increments every 4 weeks Resolution of MASH (defined as no steatotic liver disease [steatosis score of 0] or simple steatosis [a steatosis score of 1, 2, or 3] without steatohepatitis and an inflammation score of 0 or 1 and a ballooning score of 0), without worsening of fibrosis (defined as no increase in the fibrosis stage) at week 52 Primary outcome: Results In this phase 2 trial involving participants with MASH and moderate or severe fibrosis, treatment with tirzepatide for 52 weeks was more effective than placebo with respect to resolution of MASH without worsening of fibrosis
